Instrument Business Outlook Volume 34 - Issue 1

15 Apr 2025

Categories:

Instrument Business Outlook

Table of Contents

Tariffs Heighten Uncertainty for Instrument Firms
Executive Briefing
- QIAGEN Raises FY Guidance
- Bruker Q1 Results Meet Forecasts
- PacBio Announces Preliminary Results and Workforce Reductions
- Sartorius Invests in Microtissues
- Tecan to Acquire Certain Assets from Revvity
- Investors Express Further Opposition to Quanterix-Akoya
- 908 Devices Announces Preliminary Results
- Refurbished Equipment Supplier Acquired
Fourth Quarter Results: 10x Genomics, HORIBA, Oxford Nanopore, QIAGEN and Tecan
- 10x Genomics Predicts a Modest 2025 Performance
  - Q4
  - FYE
- HORIBA Records Mixed Results in Europe
  - Q4
  - FYE
- Oxford Nanopore Posts Broad-Based Growth by Market and Region
  - H2
  - FYE
- QIAGEN Surpasses Annual Sales Forecast for 2024
  - Q4
  - FYE
- Tecan Impacted by Various Weak Market Conditions
  - H2
  - FYE
Market Profile: Spectral Flow Cytometry
- Leading Vendors
- Largest Markets
- Instrument Cost
Industry Watch
- Government and R&D: NIH Indirect Cost Limit Stayed
- Clinical: Court Vacates LDT Rule
- Government and Biopharma: FDA Endorses Non-Animal Testing
Region Watch
- UK: Government Releases DSIT Funding Numbers
- China: OECD Releases Latest R&D Figures
- EU: EU Updates Toy Regulations
News
- Broad-Based Companies
  - Company Announcements
- Life Science Instruments
  - Company Announcements
  - Gene-Based Analysis
  - Company Announcements
  - Product Introduction
  - Sales & Orders of Note
  - Cell-Based Analysis
  - Company Announcements
  - Product Introductions
  - Sales & Orders of Note
  - Protein-Based Analysis
  - Company Announcements
  - Product Introductions
- Chromatography
  - Company Announcements
  - Product Introductions
  - Sales of Note
- Bioprocess Analysis
  - Company Announcements
  - Product Introductions
  - Sales & Orders of Note
Bottom Line